The recent partial success of Vertex Pharmaceuticals Incorporated’s non-opioid product VX-548 in a pair of acute pain studies positions the product as potentially the first new non-opioid analgesic to reach the market for years. But many more companies are also working on novel mechanisms for pain and the sheer variety of approaches in the clinic reflects the difficulty of breaking through in this intractable area.
Key Takeaways
- A search of the Evaluate Pharma database shows a handful of novel assets in mid- or late-stage development for pain
The prize is worth winning. The horrifying scale of addiction to and abuse of opioid-based painkillers has become clear over...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
